Evidence map›Paper›PMID 26230271›Full record

ArticlePloS one2015

Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.

Cristina Carias, Carrie Reed, Inkyu K Kim, Ivo M Foppa, Matthew Biggerstaff, Martin I Meltzer, Lyn Finelli, David L Swerdlow

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guillain-Barré syndrome and influenza vaccines: current evidence.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Moving beyond Titers.Vaccines · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cristina CariasOffice of Science and Integrated Programs, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; IHRC.INC, Atlanta, Georgia, United States of America.
Carrie ReedInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Inkyu K KimInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle Memorial Institute, Atlanta, Georgia, United States of America.
Ivo M FoppaInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Battelle Memorial Institute, Atlanta, Georgia, United States of America.
Matthew BiggerstaffInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Martin I MeltzerDivision Of Preparedness And Emerging Infections, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Lyn FinelliInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
David L SwerdlowOffice of Science and Integrated Programs, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeasonal influenza causes considerable morbidity and mortality across all age groups, and influenza vaccination was recommended in 2010 for all persons aged 6 months and above. We estimated the averted costs due to influenza vaccination, taking into account the seasonal economic burden of the disease.

methodsWe used recently published values for averted outcomes due to influenza vaccination for influenza seasons 2005-06, 2006-07, 2007-08, and 2008-09, and age cohorts 6 months-4 years, 5-19 years, 20-64 years, and 65 years and above. Costs were calculated according to a payer and societal perspective (in 2009 US$), and took into account medical costs and productivity losses.

resultsWhen taking into account direct medical costs (payer perspective), influenza vaccination was cost saving only for the older age group (65≥) in seasons 2005-06 and 2007-08. Using the same perspective, influenza vaccination resulted in total costs of $US 1.7 billion (95%CI: $US 0.3-4.0 billion) in 2006-07 and $US 1.8 billion (95%CI: $US 0.1-4.1 billion) in 2008-09. When taking into account a societal perspective (and including the averted lost earnings due to premature death) averted deaths in the older age group influenced the results, resulting in cost savings for all ages combined in season 07-08. DISCUSSION: Influenza vaccination was cost saving in the older age group (65≥) when taking into account productivity losses and, in some seasons, when taking into account medical costs only. Averted costs vary significantly per season; however, in seasons where the averted burden of deaths is high in the older age group, averted productivity losses due to premature death tilt overall seasonal results towards savings. Indirect vaccination effects and the possibility of diminished case severity due to influenza vaccination were not considered, thus the averted burden due to influenza vaccine may be even greater than reported.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCohort StudiesFemaleHealth Care CostsHumansInfantInfluenza, HumanInfluenza VaccinesMaleMiddle AgedModels, EconomicInfluenza Vaccines

Identifiers

PMID26230271
PMCPMC4521706

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.